Modern Pediatrics. Ukraine. 2021. 2(114): 67-82. doi 10.15574/SP.2021.114.67
Dorosh O. I.^1,2,3, Petronchak O. A.⁴, Guley R. V.⁴, Burianova K. I.^1,5,6, Masynnyk Yu. S.⁷, Dushar M. I.⁸, Ruda H. V.¹, Burak T. V.^1
1Сommunal noncommercial enterprise of Lviv regional council «Western Ukrainian Specialized Pediatric Medical Centre», Ukraine
²Danylo Halytsky Lviv National Medical University, Ukraine
³Hematology Clinic «Doctor Smart», Lviv, Ukraine
⁴Private limited company «Western Histology Laboratory», Lviv, Ukraine
⁵Medical Center of St. Paraskeva, Lviv, Ukraine
⁶Clinical Municipal Emergency Hospital, Lviv, Ukraine
⁷Center for Medical Innovations NOVO, Lviv, Ukraine
⁸SI «Institute of Hereditary Pathology of the NAMS of Ukraine», Lviv, Ukraine

For citation: Dorosh OI, Petronchak OA, Guley RV, Burianova KI et al. (2021). Disseminated form of Erdheim–Chester’s disease. Clinical case. Modern Pediatrics. Ukraine. 2(114): 67-82. doi 10.15574/SP.2021.114.67
Article received: Dec 11, 2020. Accepted for publication: Mar 01, 2021.

For the first time in Ukraine, the article describes the clinical case, features of diagnostic examinations and the difficulty of the verification of Erdheim—Chester disease (ECD) of a 13-year-old girl. The disease debuted with arthritis of the right knee and right ankle joints. Subsequently, there was weakness in the legs, limping, it was difficult for the child to climb the stairs. Magnetic resonance imaging (MRI) of the brain in the supra-, intratentorial and intracerebral areas revealed numerous focal lesions of the cortex, the white medulla of both hemispheres of the brain and the left hemisphere of the cerebellum. 8 months after the initial complaints, she was diagnosed with lower flaccid paraparesis, mixed paresis of the right hand, atactic syndrome, she could not stand on her toes. Based on the results of computer tomography (CT), a widespread focal lesion of the bones, the central nervous system (including the brain, membranes of the spinal cord, cranial nerves, roots and spinal nerves), lungs, liver, pancreas, kidneys, abdominal lymph nodes, peritoneum, uterus, vagina, mammary glands. Scintigraphic signs of diffuse lesions of the bones of the skull, spine, pelvis, tubular bones of the extremities. After 9 month after the appearance of primary complaints the ECD diagnosis was confirmed using histological, immunohistochemical and molecular genetic studies. Histiocytic cells were positive for antigens CD68 and CD14, and negative for CD1a, CD207, S-100 and BRAFV600E.
Our observation shows that this pathology can occur in childhood of a female person. The rarity of this disease and the variety of clinical and pathological features are a problem for clinicians and pathologists. Diagnosis of the disease is difficult and long even with the involvement of a wide range of specialists and various examination methods (ultrasound, radiography (RTG), MRI, CT.
We hope that familiarity with the wide range of pathological changes in ECD described in this message, will help practicing clinicians and pathologists diagnose disease in the early stages and effectively provide professional medical care to such patients.
The research was carried out in accordance with the principles of the Helsinki Declaration. The informed consent of the patient was obtained for conducting the studies.
No conflict of interest was declared by the authors.
Key words: Erdheim–Chester disease, histiocytosis, children, histological examination.

REFERENCES

1. Abdel-Wahab AO, Diamond EL, Patel M et al. (2014). Detection of BRAF mutations in urine and plasma cell-free DNA: application to the diagnosis and management of histiocytic disorder patients. Abstract presented at American Society of Clinical Oncology. Chicago. https://doi.org/10.1200/jco.2014.32.15_suppl.11012

2. Adam Z, Sprlakova A, Rehak Z, Koukalova R, Szturz P, Krejci M, Pour L, Zahradova L, Cervinek L, Kren L et al. (2011). Partial regression of CNS lesions of Erdheim Chester disease after treatment with 2-chlorodeox-adenosine and their full remission following treatment with lenalidomide. Klinicka onkologie: casopis Ceske a Slovenske onkologicke spolecnosti. 24: 367-381.

3. Adam Z, Szturz P, Buckova P, Cervinkova I, Koukalova R, Rehak Z, Krejci M, Pour L, Zahradova L, Hajek R et al. (2012). Interleukin-1 receptor blockade with anakinra provided cessation of fatigue, reduction in inflammation markers and regression of retroperitoneal fibrosis in a patient with Erdheim Chester disease case study and a review of literature. Vnitrni lekarstvi. 58: 313-318.

4. Alharthi MS, Calleja A, Panse P et al. (2010). Multimodality imaging showing complete cardiovascular involvement by Erdheim Chester disease. 11 (7): E25. https://doi.org/10.1093/ejechocard/jeq052; PMid:20406735

5. Allen TC, Chevez-Barrios P, Shetlar DJ, Cagle PT. (2004). Pulmonary and ophthalmic involvement with Erdheim Chester disease: a case report and review of the literature. Arch Pathol Lab Med. 128: 1428-1431. https://doi.org/10.5858/2004-128-1428-PAOIWE

6. Aouba A, Georgin-Lavialle S, Pagnoux C, Martin Silva N, Renand A, Galateau Salle F, Le Toquin S, Bensadoun H, Larousserie F, Silvera S et al. (2010). Rationale and efficacy of interleukin-1 targeting in Erdheim Chester disease. Blood. 116: 4070-4076. https://doi.org/10.1182/blood-2010-04-279240; PMid:20724540

7. Arnaud L, Hervier B, Neel A, Hamidou MA, Kahn JE, Wechsler B, Perez-Pastor G, Blomberg B, Fuzibet JG, Dubourguet F, Marinho A et al. (2011). CNS involvement and treatment with interferon-α are independent prognostic factors in Erdheim Chester disease: a multicenter survival analysis of 53 patients. Blood. 117 (10): 2778-2782. https://doi.org/10.1182/blood-2010-06-294108; PMid:21239701

8. Arnaud L, Pierre I, Beigelman-Aubry C, Capron F, Brun AL, Rigolet A, Girerd X, Weber N, Piette JC, Grenier PA, et al. (2010). Pulmonary involvement in Erdheim Chester disease: a single-center study of thirty-four patients and a review of the literature. Arthritis Rheum. 62: 3504-3512. https://doi.org/10.1002/art.27672; PMid:20662053

9. Aubart FC, Idbaih A, Galanaud D, Law Ye B, Emile JF, Charlotte F, Donadieu J, Maksud P, Seilhean D, Amoura Z, Hoang-Xuan K, Haroche J. (2020). Central nervous system involvement in Erdheim Chester disease: An observational cohort study. Neurology. 95 (20). https://doi.org/10.1212/WNL.0000000000010748; PMid:32887776

10. Aubert O, Aouba A, Deshayes S, Georgin-Lavialle S, Rieu P, Hermine O. (2012). Favorable radiological outcome of skeletal Erdheim Chester disease involvement with anakinra. Joint Bone Spine. 80: 206-207. https://doi.org/10.1016/j.jbspin.2012.07.005; PMid:22999905

11. Balink H, Hemmelder MH, de Graaf W et al. (2011). Scintigraphic diagnosis of Erdheim-Chester disease. J Clin Oncol. 29: e470-472. https://doi.org/10.1200/JCO.2010.34.0307; PMid:21422416

12. Berti A, Cavalli G, Guglielmi B, Biavasco R, Campochiaro C, Tomelleri A et al. (2017). Tocilizumab in patients with multisystem Erdheim Chester disease. Oncoimmunology. 6: e1318237. https://doi.org/10.1080/2162402X.2017.1318237; PMid:28680751 PMCid:PMC5486186

13. Braiteh F, Boxrud C, Esmaeli B, Kurzrock R. (2005). Successful treatment of Erdheim Chester disease, a non-Langerhans-cell histiocytosis, with interferon-alpha. Blood. 106: 2992-2994. https://doi.org/10.1182/blood-2005-06-2238; PMid:16020507

14. Breuil V, Brocq O, Pellegrino C, Grimaud A, Euller Ziegler L. (2002). Erdheim Chester disease: typical radiological bone features for a rare xanthogranulomatosis. Ann Rheum Dis. 61 (3): 199-200. https://doi.org/10.1136/ard.61.3.199; PMid:11830422 PMCid:PMC1754028

15. Broccoli A, Stefoni V, Faccioli L, Agostinelli C, Spinardi L, Pastore Trossello M, Zinzani PL. (2011). Bilateral orbital Erdheim Chester disease treated with 12 weekly administrations of VNCOP-B chemotherapy: a case report and a review of literature. Rheumatol Int. 32: 2209-2213. https://doi.org/10.1007/s00296-011-1998-4; PMid:21785962

16. Brun AL, Touitou Gottenberg D, Haroche J et al. (2010). Erdheim-Chester disease: CT findings of thoracic involvement. Eur Radiol. 20: 2579-2587. https://doi.org/10.1007/s00330-010-1830-7; PMid:20563815

17. Campochiaro C, Tomelleri A, Cavalli G, Berti A, Dagna L. (2015). Erdheim Chester disease. Eur J Internal Med. 26 (4): 223-229. https://doi.org/10.1016/j.ejim.2015.03.004; PMid:25865950

18. Caputo R, Marzano AV, Passoni E, Berti E. (2007). Unusual variants of non-Langerhans cell histiocytoses. 57 (6): 1031-1045. https://doi.org/10.1016/j.jaad.2007.03.014; PMid:17485142

19. Cavalli G, Guglielmi B, Berti A, Campochiaro C, Sabbadini MG, Dagna L. (2013). The multifaceted clinical presentations and manifestations of Erdheim Chester disease: comprehensive review of the literature and of 10 new cases. Ann Rheum Dis. 72 (10): 1691-1695. https://doi.org/10.1136/annrheumdis-2012-202542; PMid:23396641

20. Chester W. (1930). Uber lipoid granulomatose. Virchows Arch (Pathol Anat Phys). 279: 561-602. https://doi.org/10.1007/BF01942684

21. Cives M, Simone V, Rizzo FM, Dicuonzo F, Cristallo Lacalamita M, Ingravallo G, Silvestris F, Dammacco F. (2015). Erdheim Chester disease: a systematic review. Crit Rev Oncol Hematol. 95 (1): 1-11. https://doi.org/10.1016/j.critrevonc.2015.02.004; PMid:25744785

22. Clerico A, Ragni G, Cappelli C, Schiavetti A, Gonfiantini M, Uccini S. (2003). Erdheim Chester disease in a child. Med Pediatr Oncol. 41: 575-577. https://doi.org/10.1002/mpo.10402; PMid:14595723

23. Cohen-Aubart F, Guerin M, Poupel L, Cluzel P, Saint Charles F, Charlotte F, Arsafi Y, Emile JF, Frisdal E, Le Goff C, Donadieu J, Amoura Z, Lesnik P, Haroche J, Le Goff W. (2018). Hypoalphalipoproteinemia and BRAFV600E Mutation Are Major Predictors of Aortic Infiltration in the Erdheim Chester Disease. Arterioscler Thromb Vasc Biol. 38 (8): 1913-1925. https://doi.org/10.1161/ATVBAHA.118.310803; PMid:29930009

24. Costa IBSDS, Abdo ANR, Bittar CS, Fonseca SMR, Moraes ASHT, Kalil Filho R, Pereira J, Hajjar LA. (2018). Cardiovascular Manifestations of Erdheim Chester's Disease: A Case Series. Arq Bras Cardiol. 111 (6): 852-855. https://doi.org/10.5935/abc.20180218

25. Dagna L, Corti A, Langheim S, Guglielmi B, De Cobelli F, Doglioni C, Fragasso G, Sabbadini MG, Ferrarini M. (2012). Tumor necrosis factor alpha as a master regulator of inflammation in Erdheim Chester disease: rationale for the treatment of patients with infliximab. J Clin Oncol. 30: e286-290. https://doi.org/10.1200/JCO.2012.41.9911; PMid:22869874

26. Das JP, Xie L, Riedl CC, Hayes SA, Ginsberg MS, Halpenny DF. (2019). Cardiothoracic manifestations of Erdheim Chester disease. Br J Radiol. 92 (1104): 20190473. https://doi.org/10.1259/bjr.20190473; PMid:31386554 PMCid:PMC6913371

27. Diamond EL, Dagna L, Hyman DM, Cavalli G, Janku F, Estrada Veras J, Ferrarini M, Abdel Wahab O, Heaney ML, Scheel PJ, Feeley NK, Ferrero E, McClain KL, Vaglio A, Colby T, Arnaud L et al. (2014). Consensus guidelines for the diagnosis and clinical management of Erdheim Chester disease. Blood. 124 (4): 483-492. https://doi.org/10.1182/blood-2014-03-561381; PMid:24850756 PMCid:PMC4110656

28. Diamond EL, Durham BH, Ulaner GA et al. (2019). Efficacy of MEK inhibition in patients with histiocytic neoplasms. Nature. 567: 521-524. https://doi.org/10.1038/s41586-019-1012-y; PMid:30867592 PMCid:PMC6438729

29. Diamond EL, Subbiah V, Lockhart AC et al. (2018). Vemurafenib for BRAF V600-Mutant Erdheim Chester disease and langerhans cell histiocytosis: analysis of data from the histology-independent, phase 2, Open-label VE-BASKET Study. JAMA Oncol. 4 (3): 384-388. https://doi.org/10.1001/jamaoncol.2017.5029; PMid:29188284 PMCid:PMC5844839

30. Drier A, Haroche J, Savatovsky J, Godeneche G, Dormont D, Chiras J, Amoura Z, Bonneville F. (2010). Cerebral, facial, and orbital involvement in Erdheim-Chester disease: CT and MR imaging findings. Radiology. 255: 586-594. https://doi.org/10.1148/radiol.10090320; PMid:20413768

31. Emile JF, Abla O, Fraitag S, Horne A, Haroche J, Donadieu J et al. (2016). Revised classification of histiocytoses and neoplasms of the macrophagedendritic cell lineages. Blood. 127 (22): 2672-2681. https://doi.org/10.1182/blood-2016-01-690636; PMid:26966089 PMCid:PMC5161007

32. Eyigor S, Kirazli Y, Memis A, Basdemir G. (2005). Erdheim Chester disease: the effect of bisphosphonate treatment – a case report. Arch Phys Med Rehabil. 86: 1053-1057. https://doi.org/10.1016/j.apmr.2004.05.005; PMid:15895357

33. Ferrero E, Belloni D, Corti A, Doglioni C, Dagna L, Ferrarini M et al. (2014). TNF-alpha in Erdheim Chester disease pericardial effusion promotes endothelial leakage in vitro and is neutralized by infliximab. Rheumatology (Oxford). 53 (1): 198-200. https://doi.org/10.1093/rheumatology/ket246; PMid:23893523

34. Garcia-Gomez FJ, Acevedo-Banez I, Martinez-Castillo R, Tirado-Hospital JL, Cuenca Cuenca JI, Pachon Garrudo VM et al. (2015). The role of 18FDG, 18FDOPA PET/CT and 99mTc bone scintigraphy imaging in Erdheim Chester disease. Eur J Radiol. 84 (8): 1586-1592. https://doi.org/10.1016/j.ejrad.2015.04.022; PMid:25975897

35. Ghotra AS, Thompson K, Lopez-Mattei J, Bawa D, Hernandez R, Banchs J, Palaskas N, Iliescu C, Kim P, Yusuf SW, Hassan SA. (2018). Cardiovascular manifestations of Erdheim Chester disease. Echocardiography. 36 (2): 229-236. https://doi.org/10.1111/echo.14231; PMid:30569522

36. Haroche J, Amoura Z, Charlotte F, Salvatierra J, Wechsler B, Graux C, Brousse N, Piette JC. (2008). Imatinib mesylate for platelet-derived growth factor receptor-beta-positive Erdheim Chester histiocytosis. Blood. 111: 5413-5415. https://doi.org/10.1182/blood-2008-03-148304; PMid:18502845

37. Haroche J, Amoura Z, Dion E et al. (2004). Cardiovascular involvement, an overlooked feature of Erdheim Chester disease: report of 6 new cases and a literature review. Medicine (Baltimore). 83 (6): 371-392. https://doi.org/10.1097/01.md.0000145368.17934.91; PMid:15525849

38. Haroche J, Amoura Z, Touraine P et al. (2007). Bilateral adrenal infiltration in Erdheim-Chester disease. Report of seven cases and literature review. J Clin Endocrinol Metab. 92: 2007-2012. https://doi.org/10.1210/jc.2006-2018; PMid:17405844

39. Haroche J, Arnaud L, Amoura Z, Cohen Aulbart F, Hervier B, Charlotte F. (2014). Erdheim Chester Disease. Curr Rheumatol Rep. 16 (4): 412. https://doi.org/10.1007/s11926-014-0412-0; PMid:24532298

40. Haroche J, Arnaud L, Amoura Z. (2012). Erdheim Chester disease. Curr Opin Rheumatol. 24 (1): 53-59. https://doi.org/10.1097/BOR.0b013e32834d861d; PMid:22089098

41. Haroche J, Arnaud L, Cohen Aubart F et al. (2013). Erdheim Chester disease. Rheum Dis Clin North Am. 39 (2): 299-311. https://doi.org/10.1016/j.rdc.2013.02.011; PMid:23597965

42. Haroche J, Charlotte F, Arnaud L, von Deimling A, Helias Rodzewicz Z, Hervier B, Cohen Aubart F, Launay D, Lesot A, Mokhtari K et al. (2012). High prevalence of BRAF V600E mutations in Erdheim Chester disease but not in other non-Langerhans cell histiocytoses. Blood. 120: 2700-2703. https://doi.org/10.1182/blood-2012-05-430140; PMid:22879539

43. Haroche J, Cluzel P, Toledano D et al. (2009). Images in cardiovascular medicine. Cardiac involvement in Erdheim Chester disease: magnetic resonance and computed tomographic scan imaging in a monocentric series of 37 patients. Circulation. 119 (25): e597-e598. https://doi.org/10.1161/CIRCULATIONAHA.108.825075; PMid:19564564

44. Haroche J, Cohen Aubart F, Amoura Z. (2020). Erdheim Chester disease. Blood. (16): 1311-1318. https://doi.org/10.1182/blood.2019002766; PMid:32107533

45. Haroche J, Cohen-Aubart F, Emile JF, Arnaud L, Maksud P, Charlotte F, Cluzel P, Drier A, Hervier B, Benameur N et al. (2013). Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation. Blood. 121: 1495-1500. https://doi.org/10.1182/blood-2012-07-446286; PMid:23258922

46. Haroche J. (2014). Consensus guidelines for the diagnosis and clinical management of Erdheim Chester disease. Blood. 124 (4): 483-492. https://doi.org/10.1182/blood-2014-03-561381; PMid:24850756 PMCid:PMC4110656

47. He T, Cui L, Niu N, Wang F, Miao H, Zhao H, Gao X, Liu Ch, Yu F, Jiang Y, Wang O, Li M, Xing X, Zhou D, Li J, Cao X, Xia W. (2020). Bone mineral density and bone microarchitecture in a cohort of patients with Erdheim Chester Disease. Orphanet J Rare Dis. 15 (1): 236. https://doi.org/10.1186/s13023-020-01518-1; PMid:32887616 PMCid:PMC7487812

48. Hervier B, Arnaud L, Charlotte F, Wechsler B, Piette JC, Amoura Z, Haroche J. (2012). Treatment of Erdheim Chester disease with long-term high-dose interferon-alpha. Semin Arthritis Rheum. 41: 907-913. https://doi.org/10.1016/j.semarthrit.2011.11.004; PMid:22300602

49. Janku F, Amin HM, Yang D, Garrido Laguna I, Trent JC, Kurzrock R. (2010). Response of histiocytoses to imatinib mesylate: fire to ashes. J Clin Oncol. 28: e633-636. https://doi.org/10.1200/JCO.2010.29.9073; PMid:20733125

50. Jendro MC, Zeidler H, Rosenthal H, Haller H, Schwarz A. (2004). Improvement of Erdheim Chester disease in two patients by sequential treatment with vinblastine and mycophenolate mofetil. Clin Rheumatol. 23: 52-56. https://doi.org/10.1007/s10067-003-0801-7; PMid:14749985

51. Johnson TR, Lenhard MS, Weidinger M et al. (2009). An unusual breast tumor. Radiologe. 49: 942-945. https://doi.org/10.1007/s00117-009-1821-3; PMid:19198792

52. Karcioglu ZA, Sharara N, Boles TL, Nasr AM. (2003). Orbital xanthogranuloma: clinical and morphologic features in eight patients. Ophthal Plast Reconstr Surg. 19 (5): 372-381. https://doi.org/10.1097/01.IOP.0000083642.15174.83; PMid:14506422

53. Kenn W, Eck M, Allolio B, Jakob F, Illg A, Marx A, Konradmuellerhermelink H, Hahn D. (2000). Erdheim Chester disease: Evidence for a disease entity different from langerhans cell histiocytosis? Three cases with detailed radiological and immunohistochemical analysis. Hum Pathol. 31: 734-739. https://doi.org/10.1053/hupa.2000.8229; PMid:10872668

54. Krylov AS, Dolgushin MB, Ryzhkov AD, Odzharova AA, Shchipakhina YA, Sushentsov EA, Bliznyukov OP, Kaspshik SM, Martinovich AA, Stroganova AM, Dranko SL, Zeynalova PA, Valiev TT. (2020). Erdheim Chester disease. Literature review and clinical case. Oncohematology. 15 (2): 61-75. https://doi.org/10.17650/1818-8346-2020-15-2-61-75

55. Lachenal F, Cotton F, Desmurs Clavel H et al. (2006). Neurological manifestations and neuroradiological presentation of Erdheim-Chester disease: report of 6 cases and systematic review of the literature. J Neurol. 253: 1267-1277. https://doi.org/10.1007/s00415-006-0160-9; PMid:17063320

56. Loeffler AG, Memoli VA. (2004). Myocardial involvement in Erdheim Chester disease. Arch Pathol Lab Med. 128 (6): 682-685. https://doi.org/10.5858/2004-128-682-MIIED

57. Mazor RD, Manevich-Mazor M, Shoenfeld Y. (2013). Erdheim Chester disease: a comprehensive review of the literature. Orphanet J Rare Dis. 8: 137. https://doi.org/10.1186/1750-1172-8-137; PMid:24011030 PMCid:PMC3849848

58. Myra C, Sloper L, Tighe PJ, McIntosh RS, Stevens SE, Gregson RH, Sokal M, Haynes AP, Powell RJ. (2004). Treatment of Erdheim-Chester disease with cladribine: a rational approach. Br J Ophthalmol. 88: 844-847. https://doi.org/10.1136/bjo.2003.035584; PMid:15148234 PMCid:PMC1772168

59. Nakasu S, Tsuji A, Fuse I, Hirai H. (2007). Intracranial solitary juvenile xanthogranuloma successfully treated with stereotactic radiosurgery. J Neurooncol. 84: 99-102. https://doi.org/10.1007/s11060-007-9351-1; PMid:17332947

60. Oweity T, Scheithauer BW, Ching HS, Lei C, Wong KP. (2002). Multiple system Erdheim Chester disease with massive hypothalamic-sellar involvement and hypopituitarism. J Neurosurg. 96: 344-351. https://doi.org/10.3171/jns.2002.96.2.0344; PMid:11838810

61. Ozkaya N, Dogan A, Abdel-Wahab O. (2017). Identification and targeting of kinase alterations in histiocytic neoplasms. Hematol/Oncol Clin. 31: 705-719. https://doi.org/10.1016/j.hoc.2017.04.008; PMid:28673397 PMCid:PMC5536849

62. Ozkaya N, Rosenblum MK, Durham BH, Pichardo JD, Abdel-Wahab O, Hameed MR, Busam KJ, Travis WD, Diamond EL, Dogan A. (2018). The histopathology of Erdheim Chester disease: a comprehensive review of a molecularly characterized cohort. Mod Pathol. 31 (4): 581-597. https://doi.org/10.1038/modpathol.2017.160; PMid:29192649 PMCid:PMC6718953

63. Picarsic J, Pysher T, Zhou H, Fluchel M, Pettit T, Whitehead M, Surrey LF, Harding B, Goldstein G, Fellig Y, Weintraub M, Mobley BC, Sharples PM, Sulis ML, Diamond EL, Jaffe R, Shekdar K, Santi M. (2019). BRAF V600E mutation in Juvenile Xanthogranuloma family neoplasms of the central nervous system (CNS JXG): a revised diagnostic algorithm to include pediatric Erdheim-Chester disease. Acta Neuropathol Commun. 7 (1): 168. https://doi.org/10.1186/s40478-019-0811-6; PMid:31685033 PMCid:PMC6827236

64. Pineles SL, Liu GT, Acebes X, Arruga J, Nasta S, Glaser R, Pramick M, Fogt F, Roux PL, Gausas RE. (2011). Presence of Erdheim Chester disease and Langerhans cell histiocytosis in the same patient: a report of 2 cases. J Neuroophthalmol. 31: 217-223. https://doi.org/10.1097/WNO.0b013e31820a204e; PMid:21326112

65. Provenzano E, Barter SJ, Wright PA et al. (2010). Erdheim-chester disease presenting as bilateral clinically malignant breast masses. Am J Surg Pathol. 34: 584-588. https://doi.org/10.1097/PAS.0b013e3181d39a3d; PMid:20216377

66. Raptis DA, Raptis CA, Jokerst C, Bhalla S. (2012). Erdheim Chester disease with interatrial septum involvement. J Thorac Imaging. 27 (5): W105-107. https://doi.org/10.1097/RTI.0b013e31821db200; PMid:21681117

67. Sheu SY, Wenzel RR, Kersting C et al. (2004). Erdheim-Chester disease: case report with multisystemic manifestations including testes, thyroid, and lymph nodes, and a review of literature. J Clin Pathol. 57: 1225-1228. https://doi.org/10.1136/jcp.2004.018481; PMid:15509691 PMCid:PMC1770491

68. Simiele Narvarte A, Novoa Sanjurjo F, Gomez Rodriguez N, Anton Badiola I. (2004). Erdheim Chester disease and Langerhans histiocytosis. A fortuitous association? An Med Interna. 21: 593-596. https://doi.org/10.4321/S0212-71992004001200006; PMid:15628955

69. Song SY, Lee SW, Ryu KH, Sung SH. (2011). Erdheim Chester disease with multisystem involvement in a 4-year-old. Pediatr Radiol. 42: 632-635. https://doi.org/10.1007/s00247-011-2235-8; PMid:21879308

70. Srikulmontree T, Massey HD, Roberts WN. (2007). Treatment of skeletal Erdheim Chester disease with zoledronic acid: case report and proposed mechanisms of action. Rheumatol Int. 27: 303-307. https://doi.org/10.1007/s00296-006-0190-8; PMid:16932956

71. Tran TA, Fabre M, Pariente D, Craiu I, Haroche J, Charlotte F, Eid P, Durrbach A, Taoufik Y, Kone-Paut I. (2009). Erdheim Chester disease in childhood: a challenging diagnosis and treatment. J Pediatr Hematol Oncol. 31: 782-786. https://doi.org/10.1097/MPH.0b013e3181b76827; PMid:19755920

72. Tran TA, Pariente D, Lecron JC, Delwail A, Taoufik Y, Meinzer U. (2011). Treatment of pediatric Erdheim Chester disease with interleukin-1-targeting drugs. Arthritis Rheum. 63: 4031-4032. https://doi.org/10.1002/art.30638; PMid:21898344

73. Vaglio A, Corradi D, Maestri R, Callegari S, Buzio C, Salvarani C. (2008). Pericarditis heralding Erdheim Chester disease. Circulation. 118 (14): e511-e512. https://doi.org/10.1161/CIRCULATIONAHA.108.767467

74. Vallonthaiel AG, Mridha AR, Gamanagatti S et al. (2016). Unusual presentation of Erdheim-Chester disease in a child with acute lymphoblastic leukemia. World J Radiol. 8 (8): 757-763. https://doi.org/10.4329/wjr.v8.i8.757; PMid:27648170 PMCid:PMC5002507

75. Vega J, Cisternas M, Bergoeing M et al. (2011). Erdheim Chester disease: report of one case. Rev Med Chil. 139 (8): 1054-1059. https://doi.org/10.4067/S0034-98872011000800011; PMid:22215336

76. Veyssier Belot C, Cacoub P, Caparros Lefebvre D, Wechsler J, Brun B, Remy M, Wallaert B, Petit H, Grimaldi A, Wechsler B, Godeau P. (1996). Erdheim Chester disease. Clinical and radiologic characteristics of 59 cases. Medicine. 75: 157-169. https://doi.org/10.1097/00005792-199605000-00005; PMid:8965684

77. Volpicelli ER, Doyle L, Annes JP, Murray MF, Jacobsen E, Murphy GF, Saavedra AP. (2011). Erdheim Chester disease presenting with cutaneous involvement: a case report and literature review. J Cutan Pathol. 38: 280-285. https://doi.org/10.1111/j.1600-0560.2010.01650.x; PMid:21143617 PMCid:PMC3619727

78. Weitzman S, Jaffe R. (2005). Uncommon histiocytic disorders: the non-Langerhans cell histiocytoses. Pediatr Blood Cancer. 45 (3): 256-264. https://doi.org/10.1017/CBO9780511545252

79. White TV, Silvester NC, Otero HJ. (2016). Non-sclerotic bone involvement in Erdheim-Chester: PET/CT and MRI findings in a 15-year-old boy. Pediatr Radiol. 46 (9): 1345-1349. https://doi.org/10.1007/s00247-016-3594-y; PMid:27028532

80. Wilejto M, Abla O. (2012). Langerhans cell histiocytosis and Erdheim Chester disease. Curr Opin Rheumatol. 24 (1): 90-96. https://doi.org/10.1097/BOR.0b013e32834db53e; PMid:22157416